Axsome Therapeutics reported preliminary unaudited net product revenues of $196.0 million for the fourth quarter of 2025, representing a 65% increase over the same period in 2024. Full year 2025 net product revenues reached $638.5 million, up 66% year-over-year. These figures reflect the company’s strongest quarterly and annual growth rates since launching its central nervous system portfolio.

AUVELITY led the fourth quarter with approximately $155.1 million in net product sales and $507.1 million for the full year. SUNOSI contributed $36.7 million in the quarter and $124.8 million for the year. SYMBRAVO, commercially launched in June 2025, generated $4.1 million in the fourth quarter and $6.6 million for the full year, marking its initial commercial impact.

Axsome emphasized that these preliminary results are subject to completion of its financial closing procedures and may be adjusted. The company plans to publish finalized fourth quarter and full year 2025 financial statements upon completion of its audit and closing process, which is expected in late January. Management noted that any variations from these estimates will be detailed in the full earnings release.